2026-01-12——
Tempus AI reports preliminary 2025 data and applications revenue of ~$316 million, Insights up ~38%
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
On January 11, 2026, Tempus AI announced preliminary unaudited results for Q4 and full year 2025, reporting Data and applications revenue of approximately $316 million for the year, with Insights (data licensing) growing approximately 38%. The company also disclosed a record Total Contract Value exceeding $1.1 billion as of December 31, 2025.
What happened
- Tempus AI issued the preliminary results press release on January 11, 2026.
- Full year 2025 revenue was approximately $1.27 billion, representing ~83% growth year-over-year, including ~30% organic growth excluding Ambry.
- Full year 2025 Data and applications revenue was ~$316 million, ~31% growth year-over-year, with Insights (data licensing) growing ~38%.
- Q4 2025 Data and applications revenue was ~$100 million, ~25% year-over-year growth, with Insights growing ~68% excluding the impact of the AstraZeneca warrant in Q4 2024.
- Tempus reported Total Contract Value of >$1.1 billion as of December 31, 2025, and 2025 net revenue retention of ~126%.
- During 2025, Tempus signed data agreements with over 70 customers, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, Incyte, Servier, Aspera Biomedicines, and Whitehawk Therapeutics.
Sources
- investors.tempus.com — primary
Announced 2026-01-12